Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489337 | 1.00 | MAPT (0.56) | MAPTHPGDACHEADRA1AADRA2A | |
| SCHEMBL12340980 | 0.82 | ADRA1A (0.44) | MAPTHPGDADRA1AADRA2AADRA2B | |
| SCHEMBL25556401 | 0.82 | DRD4 (0.48) | MAPTHPGDDRD2DRD4BRD4 | |
| SCHEMBL13502655 | 0.82 | DRD4 (0.48) | MAPTHPGDDRD2DRD4BRD4 | |
| SCHEMBL28136146 | 0.80 | DRD4 (0.51) | ADRA1AADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL28865012 | 0.80 | ACHE (0.46) | MAPTHPGDACHESLC6A2HTR2A | |
| SCHEMBL28247488 | 0.80 | ADRA1A (0.45) | HPGDADRA1AADRA2AADRA2BADRA2C | |
| SCHEMBL28136177 | 0.80 | ADRA1A (0.45) | HPGDADRA1AADRA2AADRA2BADRA2C | |
| SCHEMBL22527291 | 0.80 | DRD4 (0.43) | MAPTHPGDDRD2DRD4NOTUM | |
| Hydrochloric Acid SCHEMBL4800182 | 0.79 | AADAT (0.63) | ADRA1AADRA2AADRA2BADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5255262-A | — | — | None | — | — | JP | disclosed |
| CN-116043243-A | Method for electrochemically synthesizing 3, 4-dihydro-quinolinone compounds | 桂林电子科技大学 | 2023-05-02 | — | — | CN | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8268815-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7786105-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-03 | — | — | US | disclosed |
| JP-H05255262-A | OPTICALLY ACTIVE QUINOLINONE DERIVATIVE AND ITS PRODUCTION | MITSUI TOATSU CHEM INC | 1993-10-05 | — | — | JP | disclosed |
| EP-0003532-B1 | OMEGA-(2-(N-LOWER ALKYL-BENZAMIDO)-PHENYL)-ALKANOIC ACIDS, THEIR USE AND PREPARATION, AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-04-28 | — | — | EP | disclosed |
| EP-0003532-A1 | Omega-(2-(N-lower alkyl-benzamido)-phenyl)-alkanoic acids, their use and preparation, and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | SLC6A3, GRM3, GPR3 | MAPT 1818/4885HPGD 1276/4885ACHE 2287/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | MAPT 679/4885HPGD 2207/4885ACHE 953/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | MAPT 2202/4885HPGD 1889/4885ACHE 4776/4885 |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, MC2R | MAPT 3614/4885HPGD 167/4885ACHE 3837/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | MAPT 699/4885HPGD 1608/4885ACHE 587/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | MAPT 18/4885HPGD 1454/4885ACHE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.